Charles River Laboratories Intl. Inc vs iShares TIPS Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.34B), while iShares TIPS Bond ETF trades at $104.65 (market cap $14.16B). The key difference: Charles River Laboratories Intl. Inc and iShares TIPS Bond ETF are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares TIPS Bond ETF for 61 Days on average.
| CRL | TIP | |
|---|---|---|
Market Cap | $14.34B | $14.16B |
Volume | 1,242,136 | 1,695,817 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $112.20 |
52-Week Low | $149.93 | $103.98 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $17.17B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 2.28% on the day, but maintains a bullish technical outlook with strong analyst support. The stock has consistently beaten earnings expectations in recent quarters, though profitability metrics show challenges with negative net income margins and ROE. Recent investor day presentations highlighted a refreshed growth strategy targeting 5-7% organic revenue growth and $300 million in cost savings by 2030, providing fundamental catalysts.
While CRL faces profitability headwinds and premium valuation multiples, strong analyst consensus (73% buy ratings) and a $305.50 price target suggest upside potential. Key risks include execution on margin improvement targets and ongoing cost volatility in non-human primate services. The combination of technical strength, strategic initiatives, and Wall Street support creates a favorable risk-reward profile for growth-oriented investors.
TIP trades at $104.24, showing minimal daily movement with a 0.06% gain. Technical indicators signal a bearish trend, while oscillators remain neutral. The ETF's financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.78 is scheduled for August 2026, indicating income potential amid current market volatility driven by rising bond yields and geopolitical tensions.
Outlook is cautious due to bearish technicals and macroeconomic pressures from high Treasury yields. The dividend offers a yield cushion, but investors face risks from bond market instability and inflationary concerns. Monitoring Federal Reserve policy and inflation data is critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →